SCHEMBL7142680

SCHEMBL7142680

NC(=O)CC(=O)c1occ2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.41
GAA P10253 6/20 0.41
MAPT P10636 6/20 0.41
ALDH1A1 P00352 4/20 0.41
TDP1 Q9NUW8 2/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MTNR1A P48039 1/20 0.36
OGG1 O15527 1/20 0.36
TEAD1 P28347 1/20 0.35
YAP1 P46937 1/20 0.35
TEAD4 Q15561 1/20 0.35
TEAD2 Q15562 1/20 0.35
PKM P14618 1/20 0.35
PTPN1 P18031 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135689 0.81 KDM4E (0.42) KDM4EMAPTALDH1A1TDP1HPGD
SCHEMBL649403 0.80 ALDH1A1 (0.41) KDM4EGAAMAPTALDH1A1TDP1
SCHEMBL7136142 0.80 NCEH1 (0.37) KDM4EMAPTALDH1A1TDP1HPGD
SCHEMBL27272020 0.79 KMT2A (0.38) KDM4EGAAMAPTALDH1A1TDP1
SCHEMBL9667079 0.79 PTPN1 (0.51) KDM4EGAAMAPTALDH1A1TDP1
SCHEMBL7139320 0.78 RAB9A (0.40) KDM4EMAPTALDH1A1TDP1HPGD
SCHEMBL7132527 0.77 TSHR (0.45) KDM4EMAPTALDH1A1GLAHPGD
SCHEMBL6753146 0.77 KDM4E (0.31) KDM4EGAAMAPTALDH1A1PTPN1
SCHEMBL4598953 0.77 KCNJ11 (0.33) KDM4EGAAMAPTALDH1A1PTPN1
SCHEMBL7022743 0.77 ALDH1A1 (0.43) KDM4EGAAALDH1A1GLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO KDM4E 862/4885GAA 1272/4885MAPT 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.